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time to engraftment, and underlying disease) predicted for
HHV-6 reactivation.
Comparing HSCTs with HHV-6 reactivation and those
without, survival at 100 days (77% v. 73%, p¼0.706) and
development of aGVHD (57% v. 32%, p¼0.062) were not
signiﬁcantly different. HHV-6 reactivation with > 1000
copies/mL trended towards increased development of
aGVHD (63% v. 36%, p¼0.051). Notably, aGVHD developed
signiﬁcantly less often in Haplo-Cord HSCTs compared to
HSCTs only using UCB (31% v. 61%, p¼0.022).
Based on preliminary analysis, early HHV-6 reactivation after
UCB HSCT occurs indiscriminately and does not inﬂuence
survival or incidence of aGVHD at 100 days post-trans-
plantation.Figure 1.337
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Background: HHV-6 infection, mainly encephalitis, may
cause signiﬁcant morbidity and mortality among HSCT re-
cipients. Despite the interest in HHV-6 in immunocompro-
mised patients, however, little is known about the clinical
signiﬁcance of HHV-6 DNAemia in HSCT recipients.
Methods: We reviewed the medical records of all HSCT re-
cipients with positive HHV-6 DNA in serum (n¼68) deter-
mined by real-time PCR assays between Nov 2008 and Apr
2012. We sought to determine the demographics, clinical
characteristics, and outcome of HHV-6 DNAemia in this pa-
tient population.
Results: Majority were white (43, 63%) males (35, 51%) with
a median age of 54 y (range: 2- 74 y) who had undergone
matched related (15, 22%), unrelated (19, 28%), and cord
blood (18, 26%) transplants. Melphalan-based therapy (34,
50%) was the most common conditioning regimen. Cortico-
steroids (41, 61%), tacrolimus (52,76%), and mycophenolate
(24, 35%) were commonly used. Acute GvHD was identiﬁed
in 38 pts (56%). All pts were on prophylactic dose of valacy-
clovir or acyclovir prior to the ﬁrst positive HHV-6 DNAemia
and the geometric mean titer (GMT) was 16,336 copies/mL
(range: 540 - 5431497 copies/mL) within amedian time from
HSCT of 29 d (range: 13-390 d). Main reasons for HHV-6
testing included persistent fever (40%), mental status
changes (26%), and delayed engraftment (9%). Regardless of
antiviral therapy which was administered in 62% of the pts
(foscarnet; 88%), most patients (68%) recovered with nega-
tive DNAemia, had symptom resolution (53%), or progressed
to meningoencephalitis (14%). HHV-6 related mortality
occurred in 3 pts (5%) despite antiviral therapy (2 encepha-
litis and 1 pneumonitis).
Conclusions: Despite receiving antiviral therapy, HHV-6
DNAemia progressed to end-organ disease with serious
complications in some HSCT recipients but most pts recov-
ered with or without therapy. Whether timely preemptivetherapy prevented HHV-6 end-organ disease still needs to be
determined in randomized trials.338
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Background: Allogeneic hematopoietic cell transplantation
(HCT) likely prolongs survival in high and intermediate risk
adults with acute myeloid leukemia (AML). Prior studies,
however, suggest that only about 15-20% of AML patients
especially older than 50 with abnormal cytogenetics receive
HCT. In this report, we evaluated the impact of transplant and
preparative regimen on high- or intermediate-risk AML pa-
tients treated in our center.
Methods: We retrospectively reviewed all patients who
were diagnosed with AML (non promyelocytic) in our center
between 2002 and 2012. Primary objective was to study the
impact of HCT and preparative regimen in high and inter-
mediate risk AML patients. Demographics and disease-
related variables were collected. OS was deﬁned as the time
from diagnosis to the time of death or last follow up.
Results: Between 2002 and 2012, 123 patients with high or
intermediate risk AML patients were treated at our center.
Median age at diagnosis was 60 (range 19-89). 82 patients
had high-risk features while 41 had intermediate risk fea-
tures. Median OS for all patients was 368 days.
Of these 124 patients, ﬁfty-one patients (41%) received
allogeneic HSCT at a median of 4.6 months from diagnosis.
Median age of patients who received HCT was 53 while
median age of patients who did not get HCTwas 68. Of the 51
patients who received HCT,13 patients withmedian age of 61
received a reduced toxicity/ Intensity conditioning regimen
(RIC) while 37 patients withmedian age of 49 received a fully
myelo-ablative regimen (MA). One got transplant elsewhere
with unknown regimen. Median percentage of blasts in bone
marrow at time of HCT was 3 and 3.5% for the RIC and MA
regimens, respectively. Number of patients who had 10% or
more blasts in the bone marrow at transplant was 9 of the 37
Figure 2. Fig 1.
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patients (23%) who received RIC regimen.
Median OS for patients who received HCT was 551 days
while it was 200 days for patients who did not receive HCT
(p¼0.0013) Fig1. The median OS for patients who got RIC was
1095 days but less at 434 days for MA patients but not sta-
tistically signiﬁcant (p¼0.64) Fig2. The cumulative incidence
of relapse was not different between the two groups.
Conclusion: In this small cohort of consecutive patients from
a single center, the results suggest that HCTcan be performed
in patients with high and Intermediate-risk AML patients
including older patients using RIC. RIC in older patients and
MA in younger patients did not differ in term of OS. However
this is limited by the small number of patients and a larger
prospective evaluation is needed taking into consideration
better models encompassing performance status and co-
morbidities.Fig 2.339
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Background: Myelodysplastic syndromes (MDS) are a het-
erogeneous group of malignancies characterized by
dysplasia, cytopenia, ineffective hematopoiesis and by an
increased risk of transformation to acute myeloid leukemia
(AML). Recurrent aberrant karyotypes cannot entirely ac-
count for the genetic defects that are at the basis of the
pathogenesis of MDS, as they are detected only in approxi-
mately 50% of patients.
Allogeneic hematopoietic cell transplantation (HCT) likely
prolongs survival in patients with AML and MDS. In this
report, we evaluated the impact of presence of dyspoesis in
paients with AML with or without cytogenetic (CG) abnor-
mality on outcome in our center.
Methods: We retrospectively reviewed all patients who
were diagnosed with AML (non promyelocytic) in our center
between 2002 and 2012. Primary objective was to study the
impact ofMDSwith or without CG abnormalities on outcomeof patients with AML. Demographics and disease-related
variables were collected. OS was deﬁned as the time from
diagnosis to the time of death or last contact.
Results: Between 2002 and 2012, 123 patients with high or
intermediate risk AML patients were treated at our center.
Median age at diagnosis was 60 (range 19-89). Median OS for
all patients was 368 days. Of 123 patients, 51 had MDS while
73 did not. CG abnormalities were present in 35 (68%) of
patients with dyspoetic changes. Median age of AML patients
with MDS was 59 while median age of AML without MDS
patients was 55. Median number of blasts in bone marrow
and peripheral blood in AML patients with MDSwas 38% and
6% respectively. While median number of blasts in bone
marrow and peripheral blood in AML patients without MDS
was 67% and 39% respectively. Of 51 AML patients with MDS,
14 received HCTwithmedian age of 56. Half of these received
myeloablative regimenwhile the other half received reduced
toxicity regimen.
The median survival time for AML patients without MDS
was 401 days while the median survival time for AML pa-
tients with MDS was 278 days (p ¼ 0.0201), Fig1.
For AML with MDS who received HCT, the median sur-
vival time was 586 days while it was 164.5 days for AML
patient withMDSwho did not receive HCT (p¼ 0.0013), Fig2.
Conclusion: In this small cohort from a single center, the
results suggest that AML patients with dyspoetic changes do
